Abstract: PO1646
A Study Comparing Rituximab and Modified Ponticelli (MP) Regimen in Primary Membranous Nephropathy(PMN)
Session Information
- Glomerular Diseases: Treatment and Outcomes
November 04, 2021 | Location: On-Demand, Virtual Only
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1203 Glomerular Diseases: Clinical, Outcomes, and Trials
Authors
- Kumar, Abhishek, Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, India
- Ray Chaudhury, Arpita, Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, India
- Gupta, Saugat Das, Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, India
- Mukherjee, Sriranjan, Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, India
- Sengupta, Moumita, Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, India
Group or Team Name
- IPGMER Nephrology
Background
The study was designed in December 2018 when the Gemritux trial had established Rituximab as an alternative to MP regimen in the treatment of PMN.So we designed a study comparing Rituximab and MP Regimen.
Methods
We allocated 35 adults with PMN and proteinuria >3.5 gm/day in a 3:2 ratio to MPregimen or Rituximab 375mg/m2 on days 1,8,15 and 22.The primary outcome was complete or partial remission(CR+PR)at 6 and 12 months in the 2 groups.The other findings included trends of 24 hr urine protein,albumin,creatine and seriousadverse events at 6 and 12 months in both groups.
Results
At 6 months,12 of 21 patients (57.14%) allocated to MP Regimen and 5 of 14 patients (35.71%) allocated to Rituximab experienced remission(CR+PR) (odds ratio [OR], 2.4; 95% CI, 0.596 -9.670,p value 0.10).At 12 months, 14 of 21 patients (66.66%) allocated to MP Regimen and 10 of 14 patients (71.43%) allocated to Rituximab experienced remission(CR+PR) (odds ratio [OR], 0.8; 95%CI,0.184-3.487,p value 0.383).Serious adverse events occurred in 15% of patients receiving Rituximab and in 24% receiving the MP Regimen.
Conclusion
We found No Statistically Significant difference betweenRituximab and the Modified Ponticelli Regimen in the treatment of membranous nephropathy . A head-to-head, longer follow up study comparing MP Regimen versus Rituximab is required in terms of duration of remission and side effect profile between the two treatment groups.
Time To Remission Analysis
Funding
- Government Support – Non-U.S.